…
Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Income before tax | -51.79M | -41.06M | -20.90M | -20.33M | -30.45M |
| Net income | -51.79M | -38.78M | -21.28M | -20.33M | -30.42M |
| Selling general administrative | 12.18M | 9.36M | 7.91M | 6.07M | 6.82M |
| Reconciled depreciation | 0.03M | 0.01M | 0.01M | 0.02M | 0.05M |
| Ebit | -51.78M | -41.84M | -22.89M | -20.52M | -25.94M |
| Ebitda | -51.75M | -41.52M | -22.30M | -20.32M | -25.47M |
| Depreciation and amortization | 0.03M | 0.32M | 0.59M | 0.21M | 0.48M |
| Non operating income net other | - | 2.59M | - | - | - |
| Operating income | -55.99M | -41.84M | -22.89M | -20.52M | -25.94M |
| Other operating expenses | 55.99M | 41.61M | 22.38M | 20.52M | 25.90M |
| Interest expense | 0.00M | 1.81M | 0.38M | 0.00M | 4.96M |
| Interest income | 4.21M | 0.08M | 0.06M | 0.19M | 0.06M |
| Net interest income | 4.21M | -1.73M | -0.31M | 0.19M | -4.90M |
| Income tax expense | - | -2.28M | 0.38M | -0.19M | -0.03M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 55.99M | 41.61M | 22.38M | 20.52M | 25.90M |
| Total other income expense net | -0.01M | 0.78M | 1.99M | 0.19M | -4.50M |
| Net income from continuing ops | -51.79M | -41.06M | -20.90M | -20.33M | -30.45M |
| Net income applicable to common shares | -51.79M | -41.06M | -20.90M | -20.33M | -32.72M |
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Total assets | 123.72M | 152.42M | 42.61M | 10.96M | 12.25M |
| Intangible assets | - | - | - | - | 0.03M |
| Other current assets | - | 1.69M | 0.95M | 0.56M | 0.57M |
| Total liab | 7.55M | 2.95M | 16.51M | 3.60M | 10.50M |
| Total stockholder equity | 116.17M | 149.47M | 26.10M | 7.37M | 1.75M |
| Deferred long term liab | - | - | 0.19M | 0.03M | - |
| Other current liab | 1.39M | 1.22M | 0.67M | 2.09M | 7.32M |
| Common stock | 0.04M | 0.03M | 0.01M | 0.01M | 0.21M |
| Capital stock | 0.04M | 0.03M | 0.01M | 0.01M | 0.21M |
| Retained earnings | -260.99M | -209.20M | -168.14M | -147.24M | -126.90M |
| Other liab | 0.41M | 0.41M | 0.39M | 0.21M | 2.12M |
| Other assets | 0.15M | 0.15M | 0.19M | 0.03M | 0.04M |
| Cash | 16.04M | 150.41M | 41.05M | 9.96M | 11.57M |
| Total current liabilities | 5.20M | 2.46M | 1.97M | 3.23M | 8.38M |
| Net debt | -13.56M | -150.22M | -26.63M | -9.54M | -11.56M |
| Short term debt | 0.54M | 0.11M | 0.27M | 0.24M | 0.01M |
| Short long term debt | - | - | - | - | 0.01M |
| Short long term debt total | 2.48M | 0.19M | 14.42M | 0.41M | 0.01M |
| Other stockholder equity | 377.47M | 358.63M | 194.23M | 154.59M | 128.44M |
| Property plant equipment | 2.19M | 0.02M | 0.42M | 0.42M | 0.04M |
| Total current assets | 104.91M | 152.10M | 41.99M | 10.52M | 12.14M |
| Long term investments | 16.47M | - | - | - | - |
| Net tangible assets | 116.17M | 149.47M | 26.10M | 7.37M | 1.72M |
| Short term investments | 85.86M | - | - | - | - |
| Long term debt | - | 0.41M | 13.97M | - | - |
| Accounts payable | 3.27M | 1.13M | 1.03M | 0.89M | 1.05M |
| Accumulated other comprehensive income | -0.35M | - | - | -14.00M | -0.00M |
| Common stock total equity | - | 0.03M | 0.01M | 0.01M | 0.06M |
| Retained earnings total equity | - | -209.20M | - | - | - |
| Non currrent assets other | 0.15M | 0.15M | 0.19M | 0.03M | 0.04M |
| Non current assets total | 18.81M | 0.32M | 0.62M | 0.45M | 0.11M |
| Capital lease obligations | 2.48M | 0.19M | 0.45M | 0.41M | - |
| Long term debt total | - | 0.41M | - | - | - |
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Investments | -101.46M | -101.31M | -101.31M | -101.31M | 0.23M |
| Change to liabilities | 2.14M | 0.22M | 0.14M | 0.33M | -0.93M |
| Total cashflows from investing activities | -101.46M | -101.46M | -101.46M | -101.46M | 0.23M |
| Net borrowings | - | -16.27M | 15.00M | 15.00M | 15.00M |
| Total cash from financing activities | 11.57M | 148.98M | 51.53M | 22.55M | 25.00M |
| Change to operating activities | -1.11M | -0.63M | -2.26M | -7.82M | 9.29M |
| Net income | -51.79M | -41.06M | -20.90M | -20.33M | -30.45M |
| Change in cash | -134.37M | 109.36M | 31.09M | -1.62M | 9.93M |
| Begin period cash flow | 150.41M | 41.05M | 9.96M | 11.57M | 1.65M |
| End period cash flow | 16.04M | 150.41M | 41.05M | 9.96M | 11.57M |
| Total cash from operating activities | -44.48M | -39.62M | -20.44M | -24.17M | -15.30M |
| Issuance of capital stock | 12.33M | 122.82M | 41.00M | 24.05M | 25.00M |
| Depreciation | 0.03M | 0.01M | 0.01M | 0.02M | 0.05M |
| Sale purchase of stock | - | 179.76M | - | - | - |
| Other cashflows from financing activities | -0.76M | 52.95M | 10.53M | -1.50M | 0.23M |
| Change to netincome | 6.25M | -2.86M | 2.48M | 3.64M | 2.45M |
| Capital expenditures | 0.15M | 0.15M | 0.15M | 0.15M | 0.05M |
| Cash flows other operating | - | 1.58M | - | - | - |
| Cash and cash equivalents changes | - | 109.36M | - | - | - |
| Change in working capital | 1.02M | -0.64M | -2.12M | -7.49M | 8.36M |
| Stock based compensation | 7.27M | 3.69M | 3.96M | 3.32M | 2.64M |
| Other non cash items | 0.35M | -1.61M | 0.38M | 0.22M | 4.12M |
| Free cash flow | -44.63M | -39.62M | -20.44M | -24.17M | -15.35M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| RZLT Rezolute Inc |
-0.27 6.43% |
3.93 | - | - | - | 1.17 | -0.29 |
| NVO Novo Nordisk A/S |
-1.06 2.73% |
37.81 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-5.64 1.08% |
515.02 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
- -% |
920.69 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
201 Redwood Shores Parkway, Redwood City, CA, United States, 94065
650 206 4507
57
| Name | Title | Year Born |
|---|---|---|
| Mr. Nevan Charles Elam J.D. | Founder, CEO & Director | 1967 |
| Dr. Brian Kenneth Roberts M.D. | Chief Medical Officer | 1975 |
| Mr. Chris Milks | VP & Head of Fin. | NA |
| Mr. Michael R. Deperro | Sr. VP & Head of Technical Operations | NA |
| Dr. Davelyn Eaves Hood M.B.A., M.D. | Director and Head of Scientific & Patient Affairs | NA |
| Mr. Michael Covarrubias | VP & Head of CMC | NA |
| Dr. Raj Agrawal M.D. | VP & Head of Ophthalmological Clinical Devel. | NA |
| Ms. Robyn Sweinhart | VP & Head of Quality | NA |
| Ms. Erin O'Boyle | VP & Head of Clinical Operations | NA |
| Ms. Susan Stewart J.D., L.L.M. | Chief Regulatory Officer | 1961 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.